1. Executive Summary (Confidence: High)

Memo Therapeutics (MTx) is a late-stage biotechnology company that has pioneered a proprietary platform, DROPZYLLA, to translate unique human immune responses into superior medicines. By capturing the antibody repertoires of "elite responders"—individuals who exhibit exceptional natural immunity to viral infections or cancer—MTx identifies highly potent antibodies that have been optimized by the human immune system. The company’s lead asset, potravitug, has demonstrated significant efficacy in Phase II trials for the treatment of BK polyomavirus (BKPyV) infection in kidney transplant recipients, a condition with high unmet medical need that directly impacts organ longevity. A major strategic milestone was achieved in February 2026 with a $328 million collaboration and option agreement with CSL to develop recombinant polyclonal IgG technology, further validating the industrial scalability of MTx’s platform. With a strong financial backing, including a CHF million Series C, and recent orphan drug designations in the EU, MTx is positioned as a critical player in the longevity of transplant medicine and precision oncology.